首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1935376

婴儿痉挛症治疗市场按产品类型、给药途径和地区划分

Infantile Spasm Treatment Market, By Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), By Route of Administration (Oral and Parenteral), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年01月28日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2026 年，婴儿痉挛症治疗市场价值将达到 10.8 亿美元，到 2033 年将达到 16.7 亿美元，2026 年至 2033 年的复合年增长率为 4.1%。

报告内容		报告详情
基准年：	2025	2026年市场规模：	10.8亿美元
历史数据时期：	2020年至2024年	预测期：	2026年至2033年
预测期（2026-2033年）复合年增长率：	4.10%	预计2033年价值：	16.7亿美元

婴儿痉挛症是一种罕见疾病，表现为1岁以下婴儿的癫痫发作。婴儿痉挛症会导致腿部或手臂突然抽搐，或头部快速前倾。痉挛可持续数秒。治疗婴儿痉挛症的主要药物是促肾上腺皮质激素（ACTH），但由于其副作用，医生也可能选择抗惊厥药物，例如Vigabatrin或其他类固醇疗法。

市场动态

随着中枢神经系统感染疾病的日益普遍，婴儿痉挛症的病例数量也在增加，预计这将有助于婴儿痉挛症治疗市场的扩张。根据美国国家生物技术资讯中心（NCBI）的数据，截至2018年1月，婴儿痉挛症的发生率为每10,000例活产婴儿中有2至3.5例。

政府对罕见疾病治疗的扶持措施预计将推动市场成长。例如，美国小儿科会与儿童神经病学会、儿童神经病基金会和美国急诊医师学会等合作伙伴携手，进行宣传倡议工作，找出认知差距，并拓展推广管道。

婴儿痉挛症的復发是推动婴儿痉挛症治疗市场发展的主要因素。冈山大学医院的研究人员发现，接受促肾上腺皮质激素（ACTH）治疗11至37天后，41%的研究对象病情復发。

此外，巴西政府于 2017 年修订了有关罕见疾病药物核准的监管规则。 2017 年 12 月，巴西监管机构国家卫生监督局 (ANVISA) 发布了 RDC 205/2017 号决议，其中规定了用于治疗、预防或诊断罕见疾病（例如婴儿痉挛症）的药物的临床试验、註册和良好生产规范 (GMP) 认证的特殊程序。

本次调查的主要特点

本报告对婴儿痉挛症治疗市场进行了详细分析，并以 2017 年为基准年，给出了预测期（2018-2026 年）内的市场规模和復合年增长率。
它还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本报告根据以下参数介绍了全球婴儿痉挛症治疗市场主要企业的概况：公司概况、财务表现、产品系列、市场地位、分销策略、主要发展、策略和未来计划。
本报告的研究结果将使负责人和经营团队能够就即将推出的产品、技术升级、市场扩张和行销策略做出明智的决策。
这份全球婴儿痉挛症治疗市场报告的目标受众是该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
相关人员将能够透过用于分析婴儿痉挛症治疗市场的各种策略矩阵轻鬆做出决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
非洲
- 南非
- 北非
- 中非

第七章竞争情势

热图分析
市占率分析（3x3矩阵）
公司简介
- H. Lundbeck A/S
- Mallinckrodt Pharmaceuticals
- Catalyst Pharmaceuticals
- GW Pharmaceuticals plc
- Retrophin, Inc.
- Valerion Therapeutics
- Orphelia Pharma SA
- Insys Therapeutics, Inc.
- Anavex Life Sciences Corp.

第八章分析师建议

机会
分析师观点
Coherent Opportunity Map

第九章各节

参考
调查方法

简介目录

Product Code: CMI2453

Infantile Spasm Treatment Market is estimated to be valued at USD 1.08 Bn in 2026 and is expected to reach USD 1.67 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.08 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.10%	2033 Value Projection:	USD 1.67 Bn

Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies.

Market Dynamics

Increasing prevalence of central nervous system infection, may develop infantile spasm which in turn is expected to boost the infantile spasm treatment market. According to the National Center for Biotechnology Information (NCBI), in January 2018, the prevalence of infantile spasm was 2 to 3.5 infants per 10,000 live births.

Government initiatives for rare disease treatment is expected to boost the market growth. For instance, The American Academy of Pediatrics also works with the Child Neurology Society, Child Neurology Foundation, American College of Emergency Physicians, and other partners to build advocacy, identify awareness gaps, and expand outreach opportunities.

The relapse or reoccurrence of infantile spasm is a major factor driving growth of the infantile spasm treatment market. According to investigators from Okayama University Hospital, Japan, after the treatment of infantile spasm with ACTH therapy for 11 to 37 days, the disease reoccurred in 41% of the people under study.

Moreover, the government of Brazil in year 2017 amended its regulatory rules for approving drugs for rare disease. In December 2017, Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) published Resolution RDC 205/2017, regulating special procedures for clinical trials, registration, and certification of Good Manufacturing Practices (GMPs) of drugs intended to treat, prevent or diagnose rare diseases such as infantile spasm.

Key features of the study

This report provides in-depth analysis of the infantile spasm treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global infantile spasm treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global infantile spasm treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the infantile spasm treatment market

Market Segmentation

By Product Type
- Adrenocorticotropic Hormone
- Vigabatrin
- Phase III
By Route of Administration
- Oral
- Parenteral
By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Lundbeck A/S
- Mallinckrodt Pharmaceuticals
- Catalyst Pharmaceuticals
- GW Pharmaceuticals plc
- Retrophin, Inc.
- Valerion Therapeutics
- Orphelia Pharma SA
- Insys Therapeutics, Inc.
- Anavex Life Sciences Corp.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Route of Administration
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend

4. Global Infantile Spasm Treatment Market , By Product Type, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adrenocorticotropic Hormone
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Vigabatrin
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Phase III
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Infantile Spasm Treatment Market , By Route of Administration, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Parenteral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Infantile Spasm Treatment Market , By Region, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
- H. Lundbeck A/S
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Mallinckrodt Pharmaceuticals
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Catalyst Pharmaceuticals
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- GW Pharmaceuticals plc
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Retrophin, Inc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Valerion Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Orphelia Pharma SA
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Insys Therapeutics, Inc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Anavex Life Sciences Corp.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates

8. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

婴儿痉挛症治疗市场按产品类型、给药途径和地区划分

Infantile Spasm Treatment Market, By Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), By Route of Administration (Oral and Parenteral), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

市场动态